A European Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Insulin degludec/liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 13 Jun 2017 Primary endpoint (Change in HbA1c (Hemoglobin A1c)) has been met, according to the results published at the 77th Annual Scientific Sessions of the American Diabetes Association.
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
- 10 Jun 2017 Biomarkers information updated